Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial
The effect of metoprolol on mortality was compared with that of placebo in a double blind randomised trial in patients with definite or suspected acute myocardial infarction. Treatment with metoprolol or placebo started as soon as possible after the patient's arrival in hospital and was continued for 90 days. Metoprolol was given as a 15 mg intravenous dose followed by oral administration of 100 mg twice daily. 1395 patients (697 on placebo and 698 on metoprolol) were included in the trial. Definite acute myocardial infarction developed in 809 and probable infarction in 162. Patients were allocated to various risk groups and within each group patients were randomly assigned to treatment with metoprolol or placebo. There were 62 deaths in the placebo group (8.9%) and 40 deaths in the metoprolol group (5.7%), a reduction of 36% (p less than 0.03). Mortality rates are given according to the treatment group to which the patients were initially randomly allocated.
Myocardial infarction: is bepridil, a new calcium antagonist, able to improve the course of the acute phase?
ADP-induced platelet aggregation and metoprolol treatment of myocardial infarction patients. A controlled study
Diltiazem treatment for the management of ischaemia in patients with poor left ventricular function: safety of long term administration
Occurrence of anterior ST depression in inferior myocardial infarction and relation to clinical outcome
Serum lipids and lipoproteins in ischaemic heart disease following withdrawal of long-term metoprolol treatment
Ventricular premature beats, ventricular tachycardia, and sudden cardiac death: identification of patients and drug treatment
Ventricular arrhythmias during the first year after acute myocardial infarction: influence of long-term treatment with metoprolol
Short-term and long-term tolerance to beta-blockade with alprenolol in patients admitted for a suspected acute myocardial infarction
Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk
The effect of long-term intervention with alprenolol on mortality in definite or suspected myocardial infarction
Long-term treatment with slow release oxprenolol alone, or in combination with other drugs: effects on blood pressure, lipoproteins and exercise performance
Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction
Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction
Ten year mortality in relation to original size of myocardial infarct: results from the Gothenburg metoprolol study
The clinical importance of silent ischaemia during exercise--new insights in different stages of coronary artery disease
Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction
Treatment of chronic stable angina with carvedilol: a multiple-action neurohormonal antagonist. A review of controlled clinical trials
Factors associated with the use of various medications amongst patients with severe coronary artery disease. SECOR/SBU Project Group
In-hospital mortality of elderly patients with acute myocardial infarction: data from the MITRA (Maximal Individual Therapy in Acute Myocardial Infarction) registry
Changes in rates of beta-blocker use in community hospital patients with acute myocardial infarction
Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity
Role of intravenous beta-blockers in the treatment of ST-elevation myocardial infarction: of mice (dogs, pigs) and men
Ischaemic preconditioning is related to decreasing levels of extracellular adenosine that may be metabolically useful in the at-risk myocardium: an experimental study in the pig
Studies of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease
Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome
Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines
Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality: a Swedish nationwide observational study
Favorable effects of intravenous beta blockers in ST elevation myocardial infarct: time for a revival?
Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it
Impact of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: protocol for a multicentre prospective study
Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment.
Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence
Differences in haemodynamic response to beta-blocking drugs between stable coronary artery disease and acute myocardial infarction
Secondary prevention after myocardial infarction: effects of beta blocking agents and calcium antagonists
Occurrence of hypokalemia in suspected acute myocardial infarction and its relation to clinical history and clinical course
Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity
The effects of metoprolol and dazmegrel, alone and in combination, on arrhythmias induced by coronary artery occlusion in conscious rats
Predictor function of hemorheologic parameters with reference to the incidence of manifest circulatory disorders: Concept of the Aachen study
Relationship between enzymatically estimated infarct size and short- and long-term survival after acute myocardial infarction
Appearance of T-wave inversions without raised serum enzyme activity in suspected acute myocardial infarction: clinical outcome in relation to subendocardial infarction
The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose
Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpoint
Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril
Comparative haemodynamic dose-response effects of intravenous propranolol and pindolol in patients with coronary heart disease
A highly selective beta1-adrenergic blocker with partial beta2-agonist activity derived from ferulic acid, an active component of Ligusticum wallichii Franch
Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study
Defining the utility of clinically acceptable variations in evidence-based practice guidelines for evaluation of quality improvement activities
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
Cardioselective beta-blockers in patients with asthma and concomitant heart failure or history of myocardial infarction: when do benefits outweigh risks?
Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET
Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management
Endurance exercise training attenuates cardiac beta2-adrenoceptor responsiveness and prevents ventricular fibrillation in animals susceptible to sudden death
Aspects on the intensity and the relief of pain in the prehospital phase of acute coronary syndrome: experiences from a randomized clinical trial
Targeted ablation of cardiac sympathetic neurons reduces the susceptibility to ischemia-induced sustained ventricular tachycardia in conscious rats
Effect of Beta Blockers and Renin-Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Influence of the previous use of β-blockers on the early clinical course of acute coronary syndromes
Outcome of patients with high-risk Duke treadmill score and normal myocardial perfusion imaging on spect
Use of beta-blocker is associated with lower mortality in patients with coronary artery disease with or without COPD
Secondary prevention after myocardial infarction: subgroup analysis of patients at risk in the Norwegian Timolol Multicenter Study
The relationship between the electrocardiographically estimated infarct size and 1- and 2-year survival in acute myocardial infarction
Increased occurrence of left ventricular thrombi during early treatment with timolol in patients with acute myocardial infarction
Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction
Effects of thoracic epidural anaesthesia on central haemodynamics compared to cardiac beta adrenoceptor blockade in conscious rats with acute myocardial infarction
Efficacy and safety of moricizine in patients with ventricular tachycardia: results of a placebo-controlled prospective long-term clinical trial
Should every survivor of a heart attack be given a beta-blocker? Part I. Evidence from clinical trials
Myocardial surface oxygen pressure across the border zone in the pig during acute coronary artery occlusion. A comparison of pretreatment with metoprolol or isoprenaline
The international prospective primary prevention study in hypertension (IPPPSH): objectives and methods. The IPPPSH Collaborative Group
Ambulatory monitoring of blood pressure and arrhythmias by non-invasive methods in hypertensive patients treated with metoprolol
Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker
Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists
Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction
Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol
The long-term increase of baseline and reflexly augmented levels of human vagal-cardiac nervous activity induced by scopolamine
Inhibition of platelet accumulation by beta 1-adrenoceptor blockade in the thoracic aorta of rabbits subjected to experimental sympathetic activation
Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol
Parasympathetic muscarinic stimulation limits noradrenaline induced myocardial creatine kinase release: a study in the isolated perfused working rat heart
The effect of chemical sympathectomy on mitochondrial function in the ischaemic and reperfused myocardium
Five-year mortality after acute myocardial infarction in relation to previous history, level of initial care, complications in hospital, and medication at discharge
Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials
Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review
Predictors of death and mode of death during long-term follow-up among patients with unconfirmed acute myocardial infarction
Cardiovascular medications taken by patients aged >or=70 years hospitalized for acute coronary syndromes before hospitalization and at hospital discharge
Beta-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists in treatment of elderly patients with acute myocardial infarction
Alpha 2-Adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo
Growth hormone alone or combined with metoprolol preserves cardiac function after myocardial infarction in rats
Exercise training normalizes beta-adrenoceptor expression in dogs susceptible to ventricular fibrillation
Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline
Assessment of compliance with the American College of Cardiology/American Heart Association guidelines for patients with acute coronary syndromes admitted to a tertiary care hospital coronary care unit
Beta-blocker compliance, mortality, and reinfarction: validation of clinical trial association using insurer claims data
Effect of metoprolol and amlodipine on myocardial total ischaemic burden in patients with stable angina pectoris
Effect of cardiovascular drugs on cardiovascular events in 1599 patients followed in an academic outpatient cardiology practice
Prevalence and prognostic significance of long QT interval in patients with acute coronary syndrome: review of the literature
Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication
Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review
β-Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction: recommendations, mechanisms, and concerns
Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol
Beta-blocker therapy after myocardial infarction guided by left ventricular ejection fraction: is 50 the new 40?
Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction
Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study
Long-term morbidity in patients where the initial suspicion of myocardial infarction was not confirmed
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators
Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease
Differences in refractory-period response of canine subendocardium and subepicardium to bunazosin, an alpha1-adrenoceptor antagonist, and propranolol during myocardial ischemia
Ischaemic heart disease, stroke and total mortality in women--results from a prospective population study in Gothenburg, Sweden
Differences in discharge medication after acute myocardial infarction in patients with HMO and fee-for-service medical insurance
Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants
A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias
Effects of a beta-blocker on ventricular late potentials in patients with acute anterior myocardial infarction receiving successful thrombolytic therapy
Tumor necrosis factor alpha, rapid ventricular tachyarrhythmias, and infarct size in canine models of myocardial infarction
Cardiac autonomic neural remodeling and susceptibility to sudden cardiac death: effect of endurance exercise training
Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction
Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study
Under-prescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence
Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care?
Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Real-world use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/β-blocks in Chinese patients before acute myocardial infarction occurs: patient characteristics and hospital follow-up
The role of stress and the sympathetic nervous system in hypertension and ischemic heart disease: advantages of therapy with beta-receptor blockers
Relationship between electrocardiographically estimated infarct size and clinical findings in inferior myocardial infarction
Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance
Long-term follow-up of health-related quality of life in patients with suspected acute myocardial infarction when the diagnosis was not confirmed
Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia
Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group
Quality improvement efforts and hospital performance: rates of beta-blocker prescription after acute myocardial infarction
Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy
Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release
Intrusion and confusion--the impact of medication and health professionals after acute myocardial infarction
Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction.
From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review
Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.
Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.
Chronic Fatigue Syndrome
Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.
Systemic Juvenile Idiopathic Arthritis
Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.
Chromatin Regulation and Circadian Clocks
The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.
Central Pontine Myelinolysis
Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.
Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.
Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.
Cell Atlas Along the Gut-Brain Axis
Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.
Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.